-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Adient, Lowers Price Target to $23

Benzinga·10/07/2026 21:03:40
Listen to the news
UBS analyst Joseph Spak maintains Adient (NYSE:ADNT) with a Buy and lowers the price target from $29 to $23.